Elevance Health Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Elevance Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 280.70 $ to 426.80 $ · Last price: 414.30 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Healthcare Plans
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Elevance Health Inc ELV | 89.9 | 17.7 | 0.0 | 26.0 | 5.3 | 12.6 | 37.0 |
| UnitedHealth Group Incorporated UNH | 338.6 | 29.6 | 14.9 | 19.7 | 8.1 | 11.8 | 12.8 |
| CVS Health Corp CVS | 115.6 | 40.1 | 13.7 | 13.6 | 4.1 | 7.9 | 25.9 |
| Cigna Corp CI | 72.8 | 11.9 | 7.7 | 9.1 | 5.5 | 11.3 | -4.8 |
| Humana Inc HUM | 46.3 | 41.8 | 0.0 | 13.7 | 4.7 | 10.1 | 43.3 |
| Centene Corp CNC | 33.1 | – | 3.9 | 11.4 | 5.1 | 19.4 | 107.6 |
| Molina Healthcare Inc MOH | 10.7 | 59.7 | 16.7 | 8.4 | 1.7 | 11.8 | 16.3 |
| Oscar Health Inc OSCR | 9.2 | – | 0.0 | 20.2 | 15.2 | 27.5 | 80.0 |
| Clover Health Investments Corp CLOV | 2.4 | – | -0.6 | 18.5 | 3.7 | 40.3 | 47.9 |
| Median of companies shown | 46.3 | 34.9 | 3.9 | 13.7 | 5.1 | 11.8 | 37.0 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 84,978 | 5,419 | 2,470 | 9.21 | 3,205 | 25,100 | 66,387 |
| 2017 | 90,039 | 4,985 | 3,843 | 14.35 | 4,185 | 26,503 | 71,460 |
| 2018 | 92,105 | 5,837 | 3,750 | 14.75 | 3,827 | 28,541 | 72,470 |
| 2019 | 104,213 | 6,733 | 4,807 | 18.47 | 6,061 | 31,728 | 78,254 |
| 2020 | 121,867 | 7,711 | 4,572 | 17.98 | 10,688 | 33,199 | 88,276 |
| 2021 | 138,639 | 8,946 | 6,104 | 24.73 | 8,364 | 36,060 | 97,460 |
| 2022 | 156,595 | 8,451 | 5,894 | 24.28 | 8,399 | 36,243 | 102,755 |
| 2023 | 171,340 | 8,745 | 5,987 | 25.22 | 8,061 | 39,306 | 108,928 |
| 2024 | 176,810 | 8,888 | 5,980 | 25.68 | 5,808 | 41,315 | 116,889 |
| 2025 | 199,125 | 8,112 | 5,662 | 25.53 | 4,290 | 43,882 | 121,494 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.81 | -50.20 | 45,442 | 6.60 | 0.90 | 706 | 384 |
| 2025: Q1 | 9.61 | 0.20 | 48,891 | 14.80 | 4.50 | 1,017 | 821 |
| 2025: Q2 | 7.72 | -21.70 | 49,776 | 14.00 | 3.50 | 2,054 | 1,787 |
| 2025: Q3 | 5.27 | 20.80 | 50,711 | 12.30 | 2.30 | 1,135 | 775 |
| 2025: Q4 | 2.47 | 36.30 | 49,747 | 9.50 | 1.10 | 84 | -209 |
| 2026: Q1 | 8.00 | -16.70 | 50,181 | 2.60 | 3.50 | 4,332 | 4,097 |
| 2026: Q2 | 6.71 | -13.10 | 50,474 | 1.40 | 2.90 | 1,913 | 1,626 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Aktien.Guide
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 27.16 | 27.00 – 28.25 | 196,238 | -10.3% | 21 |
| 12/31/2027 | 29.61 | 29.00 – 31.00 | 200,389 | 9.0% | 22 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 3.1% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $6.29B |
|---|---|
| Market cap | $89.91B |
| Free cash flow in year ten | $8.55B |
| Terminal value as a share of market value | 50.1% |
For comparison: over the past five years free cash flow shrank by 20.0% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 8.3%
- More than 10% revenue growth is expected for the coming year 2.2%
- Share count grows by less than 3% a year -3.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 14.2%
- Gross margin at 40% or higher and without meaningful erosion 25.6%
- Goodwill from acquisitions does not grow faster than revenue 23.3%
- Net debt below twice EBITDA 2.5 x EBITDA
- Operating cash flow covers the profits of the last three years 530 m
- Return on capital at 15% or higher, or up versus two years ago 8.0%
- Insiders hold at least 10% or are net buyers 0.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
7/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 9.9%
- Exp. sales growth 3Y > 5% 0.3%
- EBIT growth 10Y > 5% 4.6%
- Exp. EBIT growth 3Y > 5% 7.7%
- Net debt < 4x EBIT 2.9x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 9.3%
- Return on equity > 15% 130.5%
- ROCE > 15% 8.0%
- Expected return > 10% 11.5%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Wessling Erin M | EVP & Chief Legal Officer | Other | 255 | 414.78 | 105,769 |
| Sep 2, 2026 | Wessling Erin M | EVP & Chief Legal Officer | Other | 94 | 405.84 | 38,149 |
| Sep 2, 2026 | Craig Ryan R | EVP & Chief HR Officer | Other | 144 | 405.84 | 58,441 |
| Jul 17, 2026 | Boudreaux Gail | President and CEO | Buy | 2,045 | 368.25 | 753,071 |
| Jul 17, 2026 | Boudreaux Gail | President and CEO | Buy | 680 | 366.41 | 249,159 |
| Jul 17, 2026 | Peru Ramiro G | Director | Buy | 1,000 | 366.05 | 366,050 |
The company
About the Company
Elevance Health, Inc. ist mit ihren Tochtergesellschaften ein Krankenversicherungsunternehmen in den USA.
- Employees
- 96,129
- Headquarters
- Indianapolis, IN
- Address
- 220 Virginia Avenue, 46204 Indianapolis, United States
- Phone
- 833 401 1577
- Website
- elevancehealth.com
- IPO Date
- 01/02/2001
- ISIN
- US0367521038
- Stock Split
- 2:1 on 06/01/2005
Management
| Name | Title | Birth Year |
|---|---|---|
| Gail Koziara Boudreaux | President, CEO & Director | 1961 |
| Mark Bradley Kaye | Executive VP & CFO | 1980 |
| Peter David Haytaian Esq. | Special Advisor | 1970 |
| Charles Morgan Kendrick Jr. | EVP and President of Commercial & Specialty Health Benefits | 1966 |
| Felicia Farr Norwood | Executive VP & Chief Health Benefits Officer | 1960 |
| Scott Wayne Anglin | SVP, Treasurer & Chief Investment Officer | – |
| Ronald William Penczek | Senior VP, Controller & Chief Accounting Officer | 1965 |
| Nathan Allen Rich | Vice President of Investor Relations | – |
| Erin M. Wessling | Executive VP & Chief Legal Officer | 1978 |
| Julie Goon | Senior Vice President of Public Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.